RNAI-mediated inhibition of tumor necrosis factor α-related conditions
US7732421B2 · kind B2 · utility
1Cited by
2References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 17, 2007 |
| Grant date | Jun 8, 2010 |
| Priority date | — |
| Expiry date | Jan 16, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.